T1	Treatment 168 179	Thymopentin
T2	Treatment 272 290	placebo-controlled
T3	Treatment 300 427	zidovudine (AZT)-treated asymptomatic human immunodeficiency virus (HIV)-infected subjects with 200-500 CD4 cells/mm3 at entry.
T4	Treatment 450 596	prestratified by prior AZT use into stratum I (235 subjects, > 6 months AZT at entry) and stratum II (117 subjects, < or = 6 months AZT at entry).
T5	Treatment 597 778	Clinical end points, CD4 cell counts, serum p24, serum immune complex dissociated (ICD) p24, and safety variables were evaluated through 48 weeks, using an intent-to-treat analysis.
T6	Treatment 1240 1247	placebo
